Tyra Biosciences, Inc.
$28.69
-5.6%Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -14.3).
Valuation inputs: P/E -14.3, earnings yield N/A, momentum -5.6%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -46.3%, ROIC -50.1%).
Profitability stack: net margin 0.0%, ROE -46.3%, ROIC -50.1%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +8.3%, momentum -5.6%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Tyra Biosciences, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Tyra Biosciences, Inc. Fair Value Envelope
No Revenue Data
TYRA has not reported any revenue values in the available annual periods.
Tyra Biosciences, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
TYRA has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
TYRA has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
TYRA has not reported any net profit margin values in the available annual periods.
Tyra Biosciences, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Tyra Biosciences, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Tyra Biosciences, Inc. Street Expectations Map
Wall Street analysts project that TYRA stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 50.50, with estimates ranging from a low of 42.00 to a high of 59.00.
The consensus 1-year price target stands at 50.50, with estimates ranging from a low of 42.00 to a high of 59.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Analyst Conviction
Positive outlook with reasonable agreement. Analysts generally optimistic about prospects with manageable uncertainty.
Market Sentiment Insight
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Tyra Biosciences, Inc. Insider Positioning
During the last 12 months, insiders have purchased $27.26M and sold $10.97M worth of TYRA shares, resulting in $16.29M of net buying activity.
3 Months
0
0.00
14.3K
528.51K
-529K
-$529K
3-6 Months
0
0.00
27.1K
696.80K
-697K
-$697K
6-9 Months
701
6.40K
502.4K
9.11M
-9.1M
-$9.11M
9-12 Months
2.7M
27.25M
61.4K
628.26K
+26.6M
+$26.62M
Top Buyers
Ra Capital Management, L.P.
Director, 10 Percent Owner:
$15.32M
Harris Todd
Director, Officer: President And Ceo
$6.13M
Warner Douglas J
Officer: Chief Medical Officer
$2.15M
Fuhrman Alan
Officer: Chief Financial Officer
$1.83M
Bensen Daniel
Officer: Chief Operating Officer
$1.83M
Top Sellers
More Robert J
Director
$5.25M
Bensen Daniel
Officer: Chief Discovery Officer
$4.56M
Kaplan Gilla
Director
$1.16M
Insider Activity Analysis
Net Insider Sentiment
Positive insider sentiment with $16.29M net buying. Buying activity substantially exceeds selling, indicating insider confidence.
Buy/Sell Ratio
Strong buy/sell ratio. Buying is at least double the selling activity, suggesting robust insider confidence.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers vs. 3 sellers. More insiders buying than selling indicates positive sentiment.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
No Dividend Yield Data
TYRA has not reported any dividend yield values in the available annual periods.
tyra Dividend History
Learning Layer
Related Guides
Build conviction on TYRA by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.